Dompe Farmaceutici`s Biologic Oxervate (cenegermin) Receives Approval in the U.S.
Eni CEO Claudio Descalzi and Dompé farmaceutici Executive Chairman Sergio Dompé signed a Letter of Intent to launch joint research and development activities focusing on the health of people and communities in the areas where Eni operates, as well as other relevant global health issues.
Dompé farmaceutici Appoints Shannon K. Sullivan as Chief Commercial Officer Biotech
MILAN and SAN MATEO, Calif., Nov. 30, 2022 /PRNewswire/ -- Dompé farmaceutici announced new data revealing a novel function of the SARS-CoV-2 Spike (S) protein interaction with the human Estrogen Receptor Alpha (ER?) that may lead to the severe coagulopathy observed in patients with COVID-19 and a minority of subjects receiving the SARS-CoV-2 vaccine. The data published today in Science Advances[1] is a collaboration between researchers from Dompé farmaceutici, the National Institute on Drug Abuse, part of the U.S. National Institutes of Health, Johns Hopkins University, The Scripps Institute, Stanford School of Medicine, and the University of L'Aquila, in Italy.
MILAN, Italy and SAN MATEO, Calif, Feb. 9, 2022 /PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in patients with severe Sjögren's-related dry eye disease, a primary symptom of Sjögren's, which is often under-diagnosed1. This trial is part of a program that includes two randomized, double-masked, vehicle-controlled studies to be conducted at more than 10 sites in the U.S. and Europe, 2,3 and was initiated following encouraging data from a Phase 2 study, results of which will be shared at a future medical meeting. That study evaluated the efficacy and safety of cenegermin ophthalmic solution versus vehicle in patients with moderate-to-severe dry eye, including a subset of patients diagnosed with Sjögren's without an accompanying rheumatic disease.
LONDON--(BUSINESS WIRE)--Engitix Ltd (‘Engitix’), a biopharmaceutical company with a pioneering and proprietary human extracellular matrix (ECM) drug target discovery platform today announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A (“Dompé”).